Small molecule · Inhibitor of ABL1 tyrosine kinase (BCR::ABL fusion kinase) (ABL1) · developed by Takeda Pharms Usa
Ponatinib is an orally available multitargeted kinase inhibitor that binds the BCR::ABL fusion kinase, including the T315I mutant form, and also inhibits VEGFR, FGFR, PDGFR, TIE2, FLT3, KIT and RET kinases. It is studied in Philadelphia chromosome-positive leukemias, including chronic myeloid leukemia and acute lymphoblastic leukemia.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 14, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03934372 | Phase 1/2 | Acute Myeloid Leukemia | Recruiting | INCY |
| NCT03263572 | Phase 2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recruiting | AMGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Accelerated Phase Chronic Myeloid LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaBCR-ABL1 Fusion Protein ExpressionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlast Phase Chronic Myeloid LeukemiaChronic Phase Chronic Myeloid LeukemiaLeukemiaLymphomaPhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemiat(9;22)
Updated Nov 15, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →